Amy Weise

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 321 citations · Full text

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati et al. · British Journal of Cancer · 2020 · 115 citations · Full text

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

Aditya Bardia, Virginia Kaklamani, Sharon Wilks et al. · Journal of Clinical Oncology · 2021 · 106 citations · Full text

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Lee S. Rosen, Patricia LoRusso, Wen Wee et al. · Investigational New Drugs · 2016 · 83 citations

Oncology, First-in-human Phase, Medicine +7

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz et al. · Journal of Clinical Oncology · 2023 · 83 citations · Full text